Biospectra
Biospectra, Inc., headquartered in the United States, is a leading provider of high-quality raw materials for the biopharmaceutical industry. Founded in 2001, the company has established itself as a key player in the production of cell culture media, excipients, and custom manufacturing solutions, catering to the needs of biotechnology and pharmaceutical companies worldwide. With a strong focus on quality and compliance, Biospectra's core products are distinguished by their rigorous testing and validation processes, ensuring they meet the stringent requirements of regulatory bodies. The company operates primarily in the US, with significant reach in global markets, positioning itself as a trusted partner in the development of innovative therapies. Notable achievements include a commitment to sustainability and continuous improvement, reinforcing its reputation as a reliable source of biopharmaceutical materials.
DitchCarbon Score
How does Biospectra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biospectra's score of 26 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biospectra's reported carbon emissions
In 2023, BioSpectra, Inc. reported total carbon emissions of approximately 3,072,000 kg CO2e. This figure includes 171,000 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and 1,212,000 kg CO2e from Scope 2 emissions, which are associated with purchased electricity. Additionally, Scope 3 emissions accounted for about 1,609,728 kg CO2e, with significant contributions from upstream transportation and distribution (approximately 1,077,000 kg CO2e) and employee commuting (394,000 kg CO2e). BioSpectra has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 42% by 2028, in line with the Paris Agreement. This target is based on a 2022 baseline. Furthermore, the company has established a goal to reduce its total Scope 3 emissions by 50% by 2030. These targets have been validated through a streamlined process for small and medium-sized enterprises, ensuring they align with the necessary reductions to limit global warming to 1.5°C. Overall, BioSpectra's proactive approach to managing its carbon footprint reflects its commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 171,000 |
| Scope 2 | 1,212,000 |
| Scope 3 | 1,609,728 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biospectra is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
